Cochrane Review Group

Movement Disorders

25 systematic reviews in Movement Disorders ask 274 questions. 4.7% have no studies to answer them, 24.1% rest on very low certainty evidence and 44.6% reach moderate or high certainty.

Reviews

Questions

274

current versions

No studies

4.7%

Moderate or high

44.6%

No studies 13 · 4.7%Ungraded 7 · 2.6%Very low 66 · 24.1%Low 66 · 24.1%Moderate 87 · 31.8%High 35 · 12.8%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Movement Disorders

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Summary of findings for cholinesterase inhibitors vs placebo Quality of Life immediately after the intervention (EQ5D Thermometer, scale 0 to 100; and EQ5D Index Score, scale 0‐1, high score is better quality of life) · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	1 study · 121 participants	Very low
Summary of findings for cholinesterase inhibitors vs placebo Economic outcomes · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for education vs control Rate of falls (falls per person‐year) · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for education vs control Number of people who experienced one or more falls · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	Risk ratio 10.89 [1.26, 94.03]	1 study · 53 participants	Very low
Summary of findings for education vs control Number of people sustaining one or more fall‐related fractures · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for education vs control Quality of life · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for education vs control Adverse events · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for education vs control Economic outcomes · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	NR	No studies
Summary of findings for exercise plus education vs control Rate of Falls (falls per person‐year) · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	Rate ratio 0.46 [0.12, 1.85]	2 studies · 320 participants	Very low
Summary of findings for exercise plus education vs control Number of people sustaining one or more fall‐related fractures · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	Risk ratio 1.45 [0.4, 5.32]	2 studies · 320 participants	Very low
Summary of findings for exercise plus education vs control Quality of life immediately after the intervention · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	2 studies · 305 participants	Very low
Summary of findings for exercise plus education vs control Adverse events · People with Parkinson's disease Interventions for preventing falls in Parkinson's disease (2022) · Cochrane	no estimate extracted	2 studies · 343 participants	Very low

Reviews 25

Interventions for preventing falls in Parkinson's disease

Allen, NE, Canning, CG, et al. · Cochrane Database of Systematic Reviews · 2022

Movement Disorders

Thinnest evidence

Reviews 25

Interventions for preventing falls in Parkinson's disease

Botulinum toxin type A versus anticholinergics for cervical dystonia

Botulinum toxin type A therapy for cervical dystonia

Botulinum toxin type A therapy for blepharospasm

GLP‐1 receptor agonists for Parkinson's disease

Iron for the treatment of restless legs syndrome

Deep brain stimulation for dystonia

Botulinum toxin for motor and phonic tics in Tourette's syndrome

Topiramate for essential tremor

Zonisamide for essential tremor

Botulinum toxin type A versus botulinum toxin type B for cervical dystonia

Botulinum toxin type B for cervical dystonia

Opioids for restless legs syndrome

Pregabalin for essential tremor

Virtual reality for rehabilitation in Parkinson's disease

Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease

Treadmill training for patients with Parkinson's disease

Alprazolam for essential tremor

Interventions for fatigue in Parkinson's disease

Creatine for Parkinson's disease

Interventions for drooling in children with cerebral palsy

Whole‐body vibration training for patients with neurodegenerative disease

Levodopa for the treatment of restless legs syndrome

Dopamine agonists for the treatment of restless legs syndrome

Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE)